

MINERVA

3Q23 Preview: Just a scratch...

LatAm Meatpackers

Main takeaways:

(i) We expect a small increase in revenue, on a quarterly basis, given better volumes; (ii) Brazil should be the main positive highlight, due to the more favorable cattle cycle; (iii) Paraguay the main negative highlight, due to excessive rain hindering shipments; (iv) We remain optimistic about China's structural demand for beef in the long run, but in the short term we see a demand that should not sustain a high price level; (v) We believe that Paraguay should once again shine in the company's results if the climate problem ceases; (vi) We reiterate our **BUY rating**, but we have **revised our assumptions** to reflect working capital and leverage dynamics that are closer to the company's new reality following the acquisition of Marfrig's 16 plants, as well as lower short-term demand in China. In view of these changes, **we cut the 12M Target Price to R\$14.00** (vs. R\$17.00 previously), leaving the shares with an **upside of +73,91%**.

Minerva will report its 3Q23 results on November 8th, and in this report we will present our expectations for the company's figures and compare them to market expectations. We expect a **reasonable** quarter in terms of **revenue**, with **improvements in the consolidated margin**. Compared to last quarter, we should see a **slightly growing top-line**, driven by an **acceleration of ~4% in volume**, but with **prices still stable**. Looking at margins, we should see a double-digit EBITDA margin, driven by the **positive cattle cycle in Brazil**. We expect Brazil to be the main positive highlight of the quarter.

On the other hand, we expect the **negative highlight** of 3Q23 to be **Paraguay**. Even with the positive cattle cycle, we observed the **occurrence of climatic events** that made it difficult the logistics of transporting live cargo to the cattle slaughter plants difficult. We therefore believe that the volume of shipments will be affected.

Valuation and rating. For the next few quarters, our expectation is that (i) the positive cattle cycle in Brazil will continue to favor margins; (ii) the company will once again benefit from the positive cycle in Paraguay, with the adverse weather conditions having normalized; and (iii) the volume of beef exports to the US will continue to grow. As we have said in other reports we have published, given the negative cattle cycle in the US that is expected to last until the middle of 2025, along with resilient demand, our analysis is that the US will continue to receive an increasing volume of shipments from other countries, such as Brazil and Uruguay. Considering that export volumes are still low given the situation, we see room for further improvement.

Analysts

Igor Guedes

+55 (11) 3206-8248
igor.guedes@genial.com.vc

Lucas Bonventi

+55 (11) 3206-8246
lucas.bonventi@genial.com.vc

Renan Rossi

+55 (11) 3206-8245
renan.rossi@genial.com.vc

Company

BEEF3 BZ Equity

Buy

Price: R\$ 8.05 (06-Nov-2023)

Target Price 12M: R\$ 14.00

Looking more favorable than negative, we reiterate our **BUY rating** for the company's shares, but we have revised our estimates, especially with regard to leverage and working capital, and are **reducing our target price** to **R\$14.00** (vs. R\$17.00 previously). In 3Q23, we expect total revenues amounted in R\$7.5bn Genial Est (-10.9% y/y). We project EBITDA of R\$788mn Genial Est., down -2.3% y/y, but representing an expansion of +0.9 p.p. y/y in margin, which should reach 10.5%. For net income, our model reached R\$218mn Genial Est (+54.1% y/y).

In relation to consensus. Our estimates are 5.1% below consensus in terms of revenue, and in line in terms of margin.

Continued good momentum in Brazil and improvement in Uruguay. On the positive side, we should have **(i)** the positive cattle cycle in Brazil, which should enable a double-digit EBITDA margin; **(ii)** Uruguay with a small increase in revenue, given the ~3% q/q acceleration in prices and volumes, despite the fact that we are still in a negative cattle cycle; **(iii)** Colombia having received authorization from health surveillance for shipments to China. Although Minerva has not yet obtained approval for the plants, we believe that it is now only a matter of time; **(iv)** a greater volume of exports to the USA, although not at a level that we can consider high.

Argentina and Paraguay as negative highlights. On the negative side, we expect **(i)** weak volumes in Argentina, due to local economic and political volatility, and stable in relation to 2Q23 and **(ii)** Paraguay with generally very weak figures, due to the climatic problems faced in the country in this period (excessive rain).

Chinese structural demand is at slow pace but remains incremental. Our perception is that, although we saw an increase in demand in July, we also noted a significant worsening in August. Along with the reduction in demand, there was a drop in export volumes, with a subsequent rebound in September. We see the RMB/USD exchange rate as one of the factors explaining this short-term volatility. When the exchange rate indicates a devaluation of the renminbi against the dollar, volumes fall, since beef is traded as a commodity in US\$, and it becomes more expensive for China to import larger volumes.

Looking at a slightly longer time horizon, we remain bullish based on factors such as **(i)** the westernization of protein demand in China; **(ii)** the expansion of the Chinese middle class and **(iii)** beef consumption in China is still well below the world average (4kg per capita vs. ~15 OECD average). However, in the short term, we don't see demand being strong enough to sustain higher selling prices for beef. We therefore believe that in the coming quarters, even if Chinese demand contributes to sequentially higher export volumes, selling prices should remain stable.

Negative scenario in the US probably will continue to help. We believe that Minerva is already benefiting from the current scenario in the US, characterized by a negative cattle cycle, but with resilient demand for beef. As the company continues to drive more **(i)** exports' volume of commodity (processed) beef from Brazil to the US and **(ii)** exports of premium cuts from Uruguay also to US market. However, in our view, the volume of exports to the US should not yet be at a level that we can consider high.

Argentina and Paraguay as negative highlights. On the negative side, we expect **(i)** weak volumes in Argentina, due to local economic and political volatility, and stable in relation to 2Q23 and **(ii)** Paraguay with generally very weak figures, due to the climatic problems faced in the country in this period (excessive rain).

Chinese structural demand is at slow pace, but remains incremental. Our perception is that, although we saw an increase in demand in July, we also noted a significant worsening in August. Along with the reduction in demand, there was a drop in export volumes, with a subsequent rebound in September. We see the RMB/USD exchange rate as one of the factors explaining this short-term volatility. When the exchange rate indicates a devaluation of the renminbi against the dollar, volumes fall, since beef is traded as a commodity in US\$, and it becomes more expensive for China to import larger volumes.

Looking at a slightly longer time horizon, we remain bullish based on factors such as **(i)** the westernization of protein demand in China; **(ii)** the expansion of the Chinese middle class and **(iii)** beef consumption in China is still well below the world average (4kg per capita vs. ~15 OECD average). However, in the short term, we don't see demand being strong enough to sustain higher selling prices for beef. We therefore believe that in the coming quarters, even if Chinese demand contributes to sequentially higher export volumes, selling prices should remain stable.

Negative scenario in the US probably will continue to help. We believe that Minerva is already benefiting from the current scenario in the US, characterized by a negative cattle cycle, but with resilient demand for beef. As the company continues to drive more **(i)** exports' volume of commodity (processed) beef from Brazil to the US and **(ii)** exports of premium cuts from Uruguay also to US market. However, in our view, the volume of exports to the US should not yet be at a level that we can consider high.

We also see an interesting upside if Paraguay is also authorized to export to the US. For this to happen, there is still a need for approval in a public consultation in the US, given that Paraguay has already been approved for exports from a sanitary point of view. We believe there is a chance of this happening in 2024. There was no progress on this issue in 3Q23. It is worth remembering that this possible approval could also be positive for Colombia, as the country could start serving clients in Chile who would no longer be served by Paraguayan production.

Table 1. Income Statement Minerva (3Q23 Genial Est.)

(R\$ millions)	3Q23E	2Q23	% q/q	3Q22	% y/y
	Genial Est.	Reported		Reported	
Net Revenue	7.517	7.277	3,3%	8.438	-10,9%
COGS	(6.057)	(5.765)	5,1%	(6.779)	-10,7%
Gross Profit	1.460	1.512	-3,4%	1.659	-12,0%
Gross Margin (%)	19,4%	20,8%	-1,36p.p	19,7%	-0,24p.p
EBITDA	788	711	10,8%	806	-2,2%
EBITDA Margin (%)	10,5%	9,8%	0,71p.p	9,6%	0,93p.p
Net Income	218	121	80,2%	142	53,5%
Net Margin (%)	2,9%	1,7%	1,24p.p	1,7%	1,22p.p

Source: Minerva, Genial Investimentos

Our Take on Minerva

For the coming quarters, we expect revenue growth to be driven more by the volume variable, given that cattle sales prices should remain stable. The company's positive highlights should continue to come mainly from Brazil and, after the climatic problem of excessive rainfall in Paraguay, the country should once again shine in the company's results.

Recapping the latest events... At the end of August, Minerva's shares fell sharply after the conference call with analysts to announce the acquisition of 16 Marfrig plants for R\$7.5bn. Although it had accumulated a performance less affected than its peers by the market bad mood since the beginning of the year, the announcement was undoubtedly a game changer for the stock's performance. However, most likely in a different way to what management had imagined it would be. The shares closed the trading session with a drop of -18% in a single day. The announcement has undoubtedly changed (for the worse) how a significant portion of investors view the company in the short term.

At that time, we saw a flow of investors leaving Minerva to structure a long position in Marfrig. According to some institutional investors we spoke to, one company's problem became the other's difficulty. Precisely because of this transfer of the issue of higher leverage from one investment thesis to another, some investors left their long positions in Minerva aside, exerting enormous selling pressure on the shares. Marfrig, on the other hand, rose +14% in that trading session, with the justification that the amount paid by Minerva for the acquisition would go into the company's cash flow, and Marfrig's leverage would fall to more reasonable levels. Although we understand the motivations of these investors, we see some irrational points in this sudden move.

We don't ignore the fact that Marfrig now has clear benefits from reducing its leverage and maintaining a smaller operation, focused on processed products (hamburgers and meatballs).

However, our estimates point to a reduction to 3.0x Net Debt/EBITDA vs. 4.1x (ex. BRF), already benefiting from a -0.5x reduction through the initial payment of R\$1.5bn (20% of the total) in 2023, with -0.6x being reduced throughout 2024. Even so, 3x leverage is still high, and wouldn't justify getting too excited about Marfrig's performance, which is still exposed to fragile operational dynamics in the short term. This view was also proved to be right that even with this instant euphoric market reaction, the shares returned today, 2 months after the fact, to trade at exactly the same level of ~R\$6.50 from which they jumped that day, giving back 100% of the gains.

Looking at Minerva, we now see an **increase in leverage to ~3.3x Net Debt/EBITDA 23E** vs. 2.5x in our estimates before the fact, given the debt issuances to structure the operation, such as the one made in September of US\$1bn in external debt at a rate of 4.37%. We consider this new level to be high and it should contribute to a sharp reduction in the company's payout in 2024 (given that Minerva's dividend policy establishes a 50% payout only if leverage is equal to or less than 2.5x).

Marfrig's shares may have returned basically all their gains, but Minerva's didn't go back up. What ended up happening, in our view, was an opportunistic move by investors who saw that Marfrig's benefits were more evident than Minerva's, migrated from one stock to the other, and after some time, sold to pocket the gains. The vast majority didn't seem to want to take a long position in Marfrig in the medium term, and the move was much more speculative than rational.

But why didn't the buyer flow go back to Minerva then? To answer this question, we must assume that the initial reading was precisely irrational. There is evidence that Marfrig is not facing a favorable moment operationally and that the leverage, even cooling down, would still be hampering FCFE. So, it seems to us to be easier to identify that kind of dynamic than the recognition of the benefits of the acquisition in Minerva's figures in the medium term.

Although the assets, according to management, are in plug and play condition, requiring low working capital to start operations, investors seem to be wary of this condition. In fact, one of our Target Price cut adjustments came from more conservative working capital assumptions. In addition, the higher leverage, and therefore the reduced dividend payment, has scared away many investors who held long positions basically thinking about receiving proceeds. Investors seem to be looking more at short-term dynamics, and very concerned about the uncertainties that we recognize that still exist in relation to the acquisition.

Company's shares have fallen, but the investment thesis still stands. Although the shares have fallen and the flow of buyers has not yet returned, Minerva's momentum continues to be the best operationally among its peers. For us, this remains unchanged, with the favorable points in relation to our investment thesis in the company, including: **(i)** a positive cattle cycle in Brazil and Paraguay, and with a possible inflection of the cycle in Uruguay (which should occur at the end of 1H24); **(ii)** long-term structural demand from China, which should ensure growth in export volumes and **(iii)** a greater volume of exports to the US market.

It is worth noting that although we see Chinese demand as growing over a longer time horizon, in the short term we are not so optimistic. As a result, we have reduced our expectations for short time growth in volumes and, above all, for beef sales prices on the foreign market, one of the factors that contributed to our Target Price cut.

The acquisition still depends on approval by antitrust bodies in the countries where the assets are located. In Brazil, we expect CADE to approve it between the end of 2023 and the beginning of 2024. Therefore, Minerva should be able to take advantage of the positive cattle cycle in Brazil in 2024 to reduce its leverage. We emphasize that we see the cycle in Brazil reversing only in 2025, so there is plenty of time for the 11 plants acquired in Brazil (of the package of 16) to still benefit from the favorable movement. We believe this is one of the concerns investors have. Whether there would be enough time to absorb the synergies in order to generate cash flow from these assets while still taking advantage of the favorable moment in the Brazilian cattle cycle.

Just a scratch... The aspects mentioned above help us to remain bullish about Minerva. Furthermore, even though the acquisition has brought an additional dose of risk to the thesis, and there is still a certain lack of visibility regarding its effects, we believe that the market reaction has been exaggerated and that, at the current price level, there is an interesting asymmetry between the price and the fair value of the company's shares.

Certainly, there were doubts about working capital and the higher level of EBITDA generation, justified by Minerva's greater efficiency in managing the assets compared to the former operator. We don't deny that these doubts do interfere with the company's valuation, **which would justify our Target Price reduction of -R\$3.00**. So we can't say that Minerva's short-term pricing has passed unscathed. There is some degree of reasoning behind the fall, but the brutality of it seems to us to have been exaggerated. We see it more as a scratch than a deep cut. We therefore reiterate our BUY rating, with a new **12M Target Price of R\$14.00** (vs. R\$17.00 previously).

Appendix: Minerva

Figure 1. Minerva – Income Statement in R\$ Millions (Genial Est. 2023-2028)

Income Statement	2023E	2024E	2025E	2026E	2027E	2028E
Net Revenue	28.110	29.841	32.303	33.112	34.244	35.986
(-) COGS	(22.662)	(23.523)	(25.817)	(26.588)	(27.714)	(29.028)
Gross Profit	5.447	6.318	6.487	6.525	6.530	6.958
(-) Expenses	(2.794)	(2.995)	(3.245)	(3.258)	(3.380)	(3.576)
Adjusted EBITDA	2.653	3.322	3.242	3.267	3.150	3.382
(-) D&A	(537)	(458)	(494)	(509)	(515)	(517)
EBIT	2.117	2.864	2.748	2.758	2.635	2.865
(+/-) Financial Result	(1.445)	(1.649)	(1.299)	(1.126)	(1.418)	(1.331)
(-) Taxes	(94)	(199)	(237)	(267)	(199)	(251)
Net income	578	1.017	1.212	1.365	1.018	1.283
Profitability						
Net margin (%)	2,05%	3,41%	3,75%	4,12%	2,97%	3,57%

Figure 2. Minerva– Cash Flow in R\$ Millions (Genial Est. 2023-2028)

Cash Flow (FCFF)	2023E	2024E	2025E	2026E	2027E	2028E
Net Revenue	28.110	29.841	32.303	33.112	34.244	35.986
(-) COGS	(22.662)	(23.523)	(25.817)	(26.588)	(27.714)	(29.028)
Adjusted EBITDA	2.653	3.322	3.242	3.267	3.150	3.382
EBIT	2.117	2.864	2.748	2.758	2.635	2.865
(-) Taxes	(94)	(199)	(237)	(267)	(199)	(251)
(+) D&A	537	458	494	509	515	517
(+/-) Δ WK	2	(91)	7	(10)	(1)	(34)
(-) Capex	(1.356)	(1.139)	(741)	(610)	(566)	(517)
FCFF	1.206	1.893	2.271	2.379	2.383	2.580

Disclosure Section

1. GENERAL DISCLAIMER

This report has been produced by the research department (“Genial Institucional Research”) of Genial Institucional Corretora de Câmbio, Títulos e Valores Mobiliários S.A. (“GENIAL INSTITUTIONAL CCTVM”). Genial Institucional is a brand name of Genial Investimentos CCTVM.

Genial Rating

	Definition	Coverage
Buy	Expected return above +10% in relation to the Company's sector average	49%
Neutral	Expected return between +10% and -10% relative to the Company's industry average	41%
Sell	Expected return below -10% in relation to the Company's sector average	5%
under Review	Under review	5%

This report may not be reproduced or redistributed to any other person, in whole or in part, for any purpose, without the prior written consent of GENIAL INSTITUTIONAL CCTVM. GENIAL INSTITUTIONAL CCTVM accepts no liability whatsoever for the actions of third parties in this respect.

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither GENIAL INSTITUTIONAL CCTVM nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report’s preparation or publication, or any losses or damages which may arise from the use of this research report

GENIAL INSTITUTIONAL CCTVM may rely on information barriers, such as “Chinese Walls” to control the flow of information within the areas, units, divisions, groups, or affiliates of GENIAL INSTITUTIONAL CCTVM.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by GENIAL INSTITUTIONAL CCTVM with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

The locally listed shares of Brazilian companies may only be purchased by investors outside of Brazil who are “eligible investors” within the meaning of applicable laws and regulations.

2. ANALYST(S) DISCLOSURES AND CERTIFICATION

The principal analyst, IGOR GUEDES, is responsible for the content of this report and for meeting the requirements of Securities and Exchange Commission of Brazil (CVM) Instruction 598/2018.

The analysts hereby certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers and it was prepared in an independent manner, including with respect to the person and to GENIAL INSTITUTIONAL.

The analyst hereby certifies that he (she) has no connection with any individual who works for the issuer(s) discussed in this report.

The analyst hereby certifies that he (she), or his (her) spouse or companion, either directly or indirectly, in his or her own name or on behalf of a third party, does not hold any of the securities covered in this report.

The analyst hereby certifies that he (she), or his (her) spouse or companion, is not directly or indirectly involved in the purchase, disposal or brokering of the securities covered in this report.

The analyst hereby certifies that he (she), or the his (her) spouse or companion, has no direct or indirect financial interest in the issuer covered in this report (other than trading shares in investment funds, in which the analyst cannot control, directly or indirectly, the administration or management of the fund, or which do not concentrate investments in sectors or companies that are covered by reports produced by the analyst).

The analyst's compensation is, directly or indirectly, determined by income from GENIAL INSTITUTIONAL's business and financial operations.

In addition, the analysts certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

The compensation of the analyst who prepared this report is determined by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of GENIAL INSTITUTIONAL CCTVM, its affiliates and/or subsidiaries as a whole, of which investment banking, sales and trading are a part. Compensation paid to analysts is the sole responsibility of GENIAL INSTITUTIONAL CCTVM.

The analyst hereby certifies that he (she), or his (her) spouse or companion, does not serve as an officer, director, or advisory board member of the subject company.

The principal analyst is responsible for the content of this report and for meeting the requirements of Securities and Exchange Commission of Brazil (CVM) Instruction 598/2018.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

3. ADDITIONAL DISCLOSURE

- (i) This document was prepared by GENIAL INSTITUTIONAL Research and is hereby supplied for the sole purpose of providing information about companies and their securities.
- (ii) The information contained herein is provided for informational purposes only and does not constitute an offer to buy or sell, and should not be construed as a solicitation to acquire, any securities in any jurisdiction. The opinions expressed herein regarding the purchase, sale or holding of securities, or with respect to the weighting of such securities in a real or hypothetical portfolio, are based on careful analysis by the analysts who prepared this report and should not be construed by current or future investors as recommendations for any particular investment decision or action. The investor's final decision should be made considering all of the risks and fees involved. This report is based on information obtained from primary or secondary public sources, or directly from companies, and is combined with estimates and calculations prepared by GENIAL INSTITUTIONAL CCTVM. This report does not purport to be a complete statement of all material facts related to any company, industry, security or market strategy mentioned. The information has been obtained from sources believed to be reliable, but GENIAL INSTITUTIONAL CCTVM does not make any express or implied representation or warranty as to the completeness, reliability or accuracy of such information. The information, opinions, estimates and projections contained in this document are based on current data and are subject to change. Prices and availability of financial instruments are indicative only and subject to change without notice. GENIAL INSTITUTIONAL CCTVM is under no obligation to update or revise this document or to advise of any changes in such data.
- (iii) The securities discussed in this report, as well as the opinions and recommendations contained herein, may not be appropriate for every type of investor. This report does not take into account the investments objectives, financial situation or particular needs of any particular investor. Investors who wish to buy, sell or invest in securities that are covered in this report should seek independent financial advice that takes individual characteristics and needs into consideration, before making any investment decision with respect to the securities in question. Each investor should make independent investment decisions after carefully analyzing the risks, fees and commissions involved. If a financial instrument is denominated in a currency other than an investor's currency, changes in exchange rates may adversely affect the price or value of, or the income derived from the financial instrument, and the reader of this report assumes all foreign exchange risks. Income from financial instruments may vary, and therefore their price or value may rise or fall, either directly or indirectly. The information, opinions and recommendations contained in this report do not constitute and should not be interpreted as a promise or guarantee of a particular return on any investment. Past performance does not necessarily indicate future results, and no representation or warranty, express or implied, is made herein regarding future performance. Therefore, GENIAL INSTITUTIONAL CCTVM, its affiliated companies, and the analysts involved in this report take no responsibility for any direct, indirect or consequential loss resulting from the use of the information contained in this report, and anyone using this report undertakes to irrevocably indemnify GENIAL INSTITUTIONAL CCTVM and its affiliates from any claims and demands.
- (iv) Prices in this report are believed to be reliable as of the date on which this report was issued and are derived from one or more of the following: (i) sources as expressly specified alongside the relevant data; (ii) the quoted price on the main regulated market for the security in question; (iii) other public sources believed to be reliable; or (iv) GENIAL INSTITUTIONAL CCTVM's proprietary data or data available to GENIAL INSTITUTIONAL CCTVM.

- (v)** No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning GENIAL INSTITUTIONAL CCTVM, its subsidiaries and affiliates. In all cases, investors should conduct their own investigation and analysis of such information before taking or omitting to take any action in relation to securities or markets that are analyzed in this report.
- (vi)** GENIAL INSTITUTIONAL CCTVM makes no representations herein that investors will obtain profits. GENIAL INSTITUTIONAL CCTVM will not share with investors any investment profits nor accept any liability for any investment losses. Investments involve risks and investors should exercise prudence in making their investment decisions. GENIAL INSTITUTIONAL CCTVM accepts no fiduciary duties on behalf of recipients of this report and in communicating this report is not acting in a fiduciary capacity. This report is not to be relied upon in substitution for the exercise of recipient's independent judgment. Opinions, estimates, and projections expressed herein constitute the current judgment of the analyst responsible for the substance of this report as of the date on which the report was issued and are therefore subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of GENIAL INSTITUTIONAL CCTVM as a result of using different assumptions and criteria. The information, opinions and recommendations contained in this report do not constitute and should not be interpreted as a promise or guarantee of a particular return on any investment.
- (vii)** Because the personal views of analysts may differ from one another, GENIAL INSTITUTIONAL CCTVM, its subsidiaries and affiliates may have issued or may issue reports that are inconsistent with, and/or reach different conclusions from, the information presented herein. Any such opinions, estimates, and projections must not be construed as a representation that the matters referred to therein will occur. Prices and availability of financial instruments are indicative only and subject to change without notice. Income from financial instruments may vary, and therefore their price or value may rise or fall, either directly or indirectly.
- (viii)** This document may not be: (a) photocopied or duplicated in any manner, in whole or in part, and/or (b) distributed without GENIAL INSTITUTIONAL CCTVM's prior written consent. GENIAL INSTITUTIONAL CCTVM accepts no liability whatsoever for the actions of third parties in this respect.
- (ix)** Neither GENIAL INSTITUTIONAL CCTVM nor any of its affiliates, nor any of their respective directors, employees or agents, accepts any liability for any loss or damage arising out of the use of all or any part of this report.
- (x)** GENIAL INSTITUTIONAL CCTVM (or its affiliates, officers, directors or employees) may, to the extent permitted by law, have acted upon or used the information herein contained before the publication of this report and may have a position in securities issued by the companies mentioned herein and may make a market or act as a principal in any transactions in any such securities. Genial Institucional may from time to time perform investment banking or other services to, or solicit investment banking or other business from, the companies mentioned herein.

4. IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Genial Institucional CCTVM, a company authorized to engage in securities activities in Brazil. Genial Institucional CCTVM is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to “major U.S. institutional investors” in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”) and is not being provided pursuant to a soft-dollar arrangement.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Brasil Plural Securities LLC, a registered broker dealer in the United States with an office at 545 Madison Ave., New York, NY 10022, (212) 897-3737. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Genial Institucional CCTVM.

Brasil Plural Securities LLC accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority (“FINRA”) and may not be an associated person of Brasil Plural Securities LLC and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

The disclosures contained in research reports produced by GENIAL INSTITUTIONAL CCTVM and distributed by Brasil Plural Securities LLC in the U.S. shall be governed by and construed in accordance with U.S. law. This report may not be reproduced or redistributed to any other person, in whole or in part, for any purpose, without the prior written consent of GENIAL INSTITUTIONAL CCTVM. Additional information relative to the financial instruments discussed in this report is available upon request.

UK Disclaimer:

(i) This document is STRICTLY CONFIDENTIAL to the recipient, may not be distributed to the press or other media and may not be reproduced in any form. this document is directed only at persons who are “INVESTMENT PROFESSIONALS” falling within article 19(5) of the FSMA 2000 (FINANCIAL PROMOTION) ORDER 2005, or HIGH NET WORTH BODIES falling within ARTICLE 49(2) of that order (together THE “RELEVANT PERSONS”). This document must not be acted on or relied on by persons who are not RELEVANT PERSONS.

(ii) The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such other jurisdiction.

Copyright 2023 GENIAL GENIAL INSTITUTIONAL CCTVM